Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.40 |
| ▸ | CASP2 | P42575 | 1/20 | 0.38 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.36 |
| ▸ | NAAA | Q02083 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22188060 | 0.85 | FAAH (0.55) | ALOX15SMN1; SMN2MEN1KMT2ACYP1A2 | |
| SCHEMBL12438897 | 0.85 | NAAA (0.46) | ALOX15SMN1; SMN2MEN1KMT2ACYP1A2 | |
| SCHEMBL12954814 | 0.85 | SLC6A5 (0.46) | ALOX15SMN1; SMN2MEN1KMT2ACYP1A2 | |
| SCHEMBL12071641 | 0.85 | ALOX15 (0.42) | ALOX15SMN1; SMN2MEN1KMT2ACYP1A2 | |
| SCHEMBL24620412 | 0.83 | SMN1; SMN2 (0.44) | ALOX15SMN1; SMN2MEN1KMT2ACYP1A2 | |
| SCHEMBL3986924 | 0.83 | PRMT1 (0.55) | SMN1; SMN2MEN1KMT2ACYP1A2CASP2 | |
| SCHEMBL8994727 | 0.83 | PTPN1 (0.45) | ALOX15SMN1; SMN2MEN1KMT2ACYP1A2 | |
| SCHEMBL8770877 | 0.83 | PRMT1 (0.55) | SMN1; SMN2MEN1KMT2ACYP1A2CASP2 | |
| SCHEMBL27112953 | 0.83 | CASP2 (0.61) | DNM1CASP2SLC6A5FAAHNAAA | |
| SCHEMBL26870168 | 0.83 | PRMT1 (0.55) | SMN1; SMN2MEN1KMT2ACYP1A2CASP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150072997-A1 | ANTI-MALARIAL COMPOUNDS | POLYMEDIX, INC. | 2015-03-12 | — | — | US | disclosed |
| US-8796275-B2 | Anti-malarial compounds | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2014-08-05 | — | — | US | disclosed |
| US-20100081665-A1 | Anti-Malarial Compounds | CELLCEUTIX CORPORATION | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081665-A1 | Anti-Malarial Compounds | AADAC, ME2, HTRA2 | ALOX15 850/4885SMN1; SMN2 3534/4885MEN1 4052/4885 |
| US-20150072997-A1 | ANTI-MALARIAL COMPOUNDS | AADAC, ME2, HTRA2 | ALOX15 850/4885SMN1; SMN2 3534/4885MEN1 4052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.